Clinical Aspects of Vitamin D Deficiency in Multiple Sclerosis

Abstract

Introduction: Multiple Sclerosis (MS) is a multifactorial, immune-mediated disorder that occurs in genetically predisposed people. Vitamin D might be an important environmental factor in the development and prevention of MS disease. We aimed to investigate the role of vitamin D in MS disease activity. Material and Methods: The study was designed as a prospective study. Thirty-two patients and 15 healthy subjects were included. Variables were MS disease duration, number of relapses, Expanded Disability Status Scale (EDSS) scores, serum vitamin D levels, assessments through neuropsychological tests relevant to depression, cognition, anxiety and fatigue. Results: The mean age of the subjects was 32.6±6.9 years. A significant positive correlation was found between the vitamin D level during relapse and remission. A statistically significant difference was found between the patients in relapse and controls in serum vitamin D levels (p=0.002). A statistically significant difference was found between the patients in relapse and patients in remission, in serum vitamin D concentrations (p<0.001). Statistically significant differences were found between the patients in relapse and controls in MMSE, Beck Depression Inventory, Benedict's Cognition Test, Fatigue Severity Scale, PASAT, State-Trait Anxiety Inventory scores (p=0.01, p<0.001, p=0.01, p<0.001, p=0.007, p<0.001 and p<0.001, respectively). Conclusion: Vitamin D in association with other therapies may prevent the progression of MS-related disabilities and the relapses in RRMS. Vitamin D levels may have effects on the symptoms (depression, anxiety, cognitive deterioration, and fatigue) which are frequently seen in the course of MS.

Keywords

• Multiple Sclerosis
• Vitamin D
• Cognition,
• Disability
• Psychiatric comorbidity

References

1. Smolders J, Menheere P, Kessels A, Damoiseaux J, Hupperts R. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler. 2008 Nov;14(9):1220-4. doi: 10.1177/1352458508094399.
2. Soilu-Hänninen M, Laaksonen M, Laitinen I, Erälinna JP, Lilius EM, Mononen I. A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2008 Feb;79(2):152-7. doi: 10.1136/jnnp.2006.105320.
3. Cantorna MT. Vitamin D and multiple sclerosis: an update. Nutr Rev. 2008 Oct;66(10 Suppl 2):S135-8. doi: 10.1111/j.1753-4887.2008.00097.x.
4. Jameson JL, Weetman AP. Tiroid bezi hastalıkları. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, eds. Çeviri editörü: Sağlıker Y. Harrison İç Hastalıkları Prensipleri. 15th ed. Istanbul: Nobel Matbaacılık; 2004:2060-75.
5. Soilu-Hänninen M, Airas L, Mononen I, Heikkilä A, Viljanen M, Hänninen A. 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis. Mult Scler. 2005 Jun;11(3):266-71. doi: 10.1191/1352458505ms1157oa.
6. Smolders J. Vitamin D and multiple sclerosis: correlation, causality, and controversy. Autoimmune Dis. 2010 Oct 5;2011:629538. doi: 10.4061/2011/629538.
7. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011 Feb;69(2):292-302. doi: 10.1002/ana.22366.
8. Armutlu K, Korkmaz NC, Keser I, Sumbuloglu V, Akbiyik DI, Guney Z, Karabudak R. The validity and reliability of the Fatigue Severity Scale in Turkish multiple sclerosis patients. Int J Rehabil Res. 2007 Mar;30(1):81-5. doi: 10.1097/MRR.0b013e3280146ec4.

9. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989 Oct;46(10):1121-3. doi: 10.1001/archneur.1989.00520460115022.
10. Lezak MD. Memory I: Tests. In: Lezak MD, ed. Neuropsychological Assessment. 3rd ed. New York, NY: Oxford University Press; 1995:429-98.
11. Forn C, Belenguer A, Belloch V, Sanjuan A, Parcet MA, Avila C. Anatomical and functional differences between the Paced Auditory Serial Addition Test and the Symbol Digit Modalities Test. J Clin Exp Neuropsychol. 2011 Jan;33(1):42-50. doi: 10.1080/13803395.2010.481620.
12. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961 Jun;4:561-71. doi: 10.1001/archpsyc.1961.01710120031004.
13. Aydemir Ö, Köroğlu E. Psikiyatride kullanılan klinik ölçekler. Hekimler Yayın Birliği. 2006;121-291.
14. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189-98. doi: 10.1016/0022-3956(75)90026-6.
15. Benedict RH, Munschauer F, Linn R, Miller C, Murphy E, Foley F, Jacobs L. Screening for multiple sclerosis cognitive impairment using a self-administered 15-item questionnaire. Mult Scler. 2003 Feb;9(1):95-101. doi: 10.1191/1352458503ms861oa.
16. Peelen E, Knippenberg S, Muris AH, Thewissen M, Smolders J, Tervaert JW, Hupperts R, Damoiseaux J. Effects of vitamin D on the peripheral adaptive immune system: a review. Autoimmun Rev. 2011 Oct;10(12):733-43. doi: 10.1016/j.autrev.2011.05.002.
17. Dörr J, Döring A, Paul F. Can we prevent or treat multiple sclerosis by individualised vitamin D supply? EPMA J. 2013 Jan 29;4(1):4. doi: 10.1186/1878-5085-4-4.
18. Orbach H, Zandman-Goddard G, Amital H, Barak V, Szekanecz Z, Szucs G, Danko K, Nagy E, Csepany T, Carvalho JF, Doria A, Shoenfeld Y. Novel biomarkers in autoimmune diseases: prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases. Ann N Y Acad Sci. 2007 Aug;1109:385-400. doi: 10.1196/annals.1398.044.
19. Smolders J, Menheere P, Thewissen M, Peelen E, Tervaert JW, Hupperts R, Damoiseaux J. Regulatory T cell function correlates with serum 25-hydroxyvitamin D, but not with 1,25-dihydroxyvitamin D, parathyroid hormone and calcium levels in patients with relapsing remitting multiple sclerosis. J Steroid Biochem Mol Biol. 2010 Jul;121(1-2):243-6. doi: 10.1016/j.jsbmb.2010.03.001.
20. van der Mei IA, Ponsonby AL, Dwyer T, Blizzard L, Taylor BV, Kilpatrick T, Butzkueven H, McMichael AJ. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J Neurol. 2007 May;254(5):581-90. doi: 10.1007/s00415-006-0315-8.
21. Simpson S Jr, Taylor B, Blizzard L, Ponsonby AL, Pittas F, Tremlett H, Dwyer T, Gies P, van der Mei I. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol. 2010 Aug;68(2):193-203. doi: 10.1002/ana.22043.
22. Pierrot-Deseilligny C, Souberbielle JC. Widespread vitamin D insufficiency: A new challenge for primary prevention, with particular reference to multiple sclerosis. Presse Med. 2011 Apr;40(4 Pt 1):349-56. doi: 10.1016/j.lpm.2011.01.003.
23. Jagannath VA, Filippini G, Di Pietrantonj C, Asokan GV, Robak EW, Whamond L, Robinson SA. Vitamin D for the management of multiple sclerosis. Cochrane Database Syst Rev. 2018 Sep 24;9(9):CD008422. doi: 10.1002/14651858.CD008422.pub3.
24. Hanwell HE, Banwell B. Assessment of evidence for a protective role of vitamin D in multiple sclerosis. Biochim Biophys Acta. 2011 Feb;1812(2):202-12. doi: 10.1016/j.bbadis.2010.07.017.
25. Burton JM, Kimball S, Vieth R, Bar-Or A, Dosch HM, Cheung R, Gagne D, D'Souza C, Ursell M, O'Connor P. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology. 2010 Jun 8;74(23):1852-9. doi: 10.1212/WNL.0b013e3181e1cec2.
26. Smolders J, Hupperts R, Barkhof F, Grimaldi LM, Holmoy T, Killestein J, Rieckmann P, Schluep M, Vieth R, Hostalek U, Ghazi-Visser L, Beelke M; SOLAR study group. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. J Neurol Sci. 2011 Dec 15;311(1-2):44-9. doi: 10.1016/j.jns.2011.04.013.
27. Kimball SM, Ursell MR, O'Connor P, Vieth R. Safety of vitamin D3 in adults with multiple sclerosis. Am J Clin Nutr. 2007 Sep;86(3):645-51. doi: 10.1093/ajcn/86.3.645.
28. Bell DS. Protean manifestations of vitamin D deficiency, part 2: deficiency and its association with autoimmune disease, cancer, infection, asthma, dermopathies, insulin resistance, and type 2 diabetes. South Med J. 2011 May;104(5):335-9. doi: 10.1097/01.SMJ.0000397893.94525.0e.
29. Kivity S, Agmon-Levin N, Zisappl M, Shapira Y, Nagy EV, Dankó K, Szekanecz Z, Langevitz P, Shoenfeld Y. Vitamin D and autoimmune thyroid diseases. Cell Mol Immunol. 2011 May;8(3):243-7. doi: 10.1038/cmi.2010.73.
30. Zhang HL, Wu J. Role of vitamin D in immune responses and autoimmune diseases, with emphasis on its role in multiple sclerosis. Neurosci Bull. 2010 Dec;26(6):445-54. doi: 10.1007/s12264-010-0731-8.
31. Smolders J, Damoiseaux J, Menheere P, Hupperts R. Vitamin D as an immune modulator in multiple sclerosis, a review. J Neuroimmunol. 2008 Feb;194(1-2):7-17. doi: 10.1016/j.jneuroim.2007.11.014.
32. Tetlow LC, Woolley DE. The effects of 1 alpha,25-dihydroxyvitamin D(3) on matrix metalloproteinase and prostaglandin E(2) production by cells of the rheumatoid lesion. Arthritis Res. 1999;1(1):63-70. doi: 10.1186/ar12.
33. Gezen-Ak D, Dursun E, Yilmazer S. The effects of vitamin D receptor silencing on the expression of LVSCC-A1C and LVSCC-A1D and the release of NGF in cortical neurons. PLoS One. 2011 Mar 3;6(3):e17553. doi: 10.1371/journal.pone.0017553.
34. Buell JS, Tucker KL. The value of physiologic vitamin D as a biomarker of dementia. Drugs Today (Barc). 2011 Mar;47(3):223-31. doi: 10.1358/dot.2011.47.3.1517492.
35. Kesby JP, Eyles DW, Burne TH, McGrath JJ. The effects of vitamin D on brain development and adult brain function. Mol Cell Endocrinol. 2011 Dec 5;347(1-2):121-7. doi: 10.1016/j.mce.2011.05.014.
36. Nimitphong H, Holick MF. Vitamin D, neurocognitive functioning and immunocompetence. Curr Opin Clin Nutr Metab Care. 2011 Jan;14(1):7-14. doi: 10.1097/MCO.0b013e3283414c38.
37. Howland RH. Vitamin D and depression. J Psychosoc Nurs Ment Health Serv. 2011 Feb;49(2):15-8. doi: 10.3928/02793695-20110111-02.
38. Thacher TD, Clarke BL. . Vitamin D insufficiency. Mayo Clin Proc. 2011 Jan;86(1):50-60. doi: 10.4065/mcp.2010.0567.
39. Stalpers-Konijnenburg SC, Marijnissen RM, Gaasbeek AB, Oude Voshaar RC. [Can I have some sunshine to cheer me up? vitamin D deficiency and depression in the elderly]. Tijdschr Psychiatr. 2011;53(6):365-70.
40. Murphy PK, Mueller M, Hulsey TC, Ebeling MD, Wagner CL. An exploratory study of postpartum depression and vitamin D. J Am Psychiatr Nurses Assoc. 2010 May;16(3):170-7. doi: 10.1177/1078390310370476.
41. Molnar E, Gonda X, Rihmer Z, Bagdy G. [Etiopathology and therapy of seasonal affective disorder]. Neuropsychopharmacol Hung. 2010 Dec;12(4):483-94.
42. Sanders KM, Stuart AL, Williamson EJ, Jacka FN, Dodd S, Nicholson G, Berk M. Annual high-dose vitamin D3 and mental well-being: randomised controlled trial. Br J Psychiatry. 2011 May;198(5):357-64. doi: 10.1192/bjp.bp.110.087544.
43. Zender R, Olshansky E. Women's mental health: depression and anxiety. Nurs Clin North Am. 2009 Sep;44(3):355-64. doi: 10.1016/j.cnur.2009.06.002.
44. Armstrong DJ, Meenagh GK, Bickle I, Lee AS, Curran ES, Finch MB. Vitamin D deficiency is associated with anxiety and depression in fibromyalgia. Clin Rheumatol. 2007 Apr;26(4):551-4. doi: 10.1007/s10067-006-0348-5.
45. Hoeck AD, Pall ML. Will vitamin D supplementation ameliorate diseases characterized by chronic inflammation and fatigue? Med Hypotheses. 2011 Feb;76(2):208-13. doi: 10.1016/j.mehy.2010.09.032.
46. Knutsen KV, Brekke M, Gjelstad S, Lagerløv P. Vitamin D status in patients with musculoskeletal pain, fatigue and headache: a cross-sectional descriptive study in a multi-ethnic general practice in Norway. Scand J Prim Health Care. 2010 Sep;28(3):166-71. doi: 10.3109/02813432.2010.505407.
47. Berkovitz S, Ambler G, Jenkins M, Thurgood S. Serum 25-hydroxy vitamin D levels in chronic fatigue syndrome: a retrospective survey. Int J Vitam Nutr Res. 2009 Jul;79(4):250-4. doi: 10.1024/0300-9831.79.4.250.
48. Knippenberg S, Bol Y, Damoiseaux J, Hupperts R, Smolders J. Vitamin D status in patients with MS is negatively correlated with depression, but not with fatigue. Acta Neurol Scand. 2011 Sep;124(3):171-5. doi: 10.1111/j.1600-0404.2010.01447.x.